Recent studies have also shown an association between mutations in the RNA polymerase, POLR3A, with development of a specific autoantibody in scleroderma patients with cancer (anti-RNA polymerase I/III antibodies) [36], suggesting that pathogenic autoimmunity among some scleroderma cases may arise from an immune response to mutated tumor antigens. Here, POLR3A is linked to neoplasm.